What Next For Medtech And Investors Post-Coronavirus?
Executive Summary
If a post-COVID-19 economic recovery starts properly in September, as some have suggested, how swift would a return to normal be for medtech and life sciences businesses? It depends what the new normal looks like, suggests life sciences legal firm Goodwin. But in the regulatory arena, agencies are working hard to keep market access a priority during the ongoing public health emergency.
You may also be interested in...
‘Restarting Is Harder Than Stopping’: UK Elective Care Faces Challenges Beyond COVID-19
Elective surgery is only “elective” in terms of timing, and is not optional. So says British Orthopaedic Association VP-elect John Skinner in the context of how post-COVID-19 planned care will move forward in the UK.
DTx And Drug Deal Sees Closed Loop Medicine And Teva Team Up On Precision Care
Medicines are still typically prescribed based on average effects in a population and rarely dose-optimized for the individual, says Closed Loop Medicine. The company sees a new strategic partnership with Teva UK as another step in advancing personalized medicine.
Swiss-EU Standoff Set To End? Medtechs Eye MRA Action
Negotiations aimed at renewing the close trading relationship and barrier-free mutual market access between Switzerland and the EU got underway on 19 March. Swiss medtech companies welcomed the move, stressing the need for the defunct mutual recognition agreement to be updated.